[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522161":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":58,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":18,"enrollmentInfo":73,"targetDuration":18,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":41,"whyStopped":18,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University Hospital, Antwerp","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CytoSorb hemoadsorption","ACTIVE_COMPARATOR","Patients with acute on chronic liver failure will receive CytoSorb treatment for 72 hours. The aim is to remove the molecules that drive systemic inflammation.",[13],"Device: CytoSorb",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Historical group that received only standard medical care",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","CytoSorb","Application of CytoSorb treatment for 72 hours in patients with ACLF",[9],[26],{"name":27,"affiliation":5,"role":28},"Karolien Dams","PRINCIPAL_INVESTIGATOR",[30,34],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","+3238215175","Karolien.Dams@uza.be",{"name":35,"role":31,"phone":36,"phoneExt":18,"email":37},"Rita Jacobs","+3238214795","rita.jacobs2@uza.be",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"UZA","RECRUITING","Edegem","Antwerp","2650","Belgium","BE",{"type":48,"coordinates":49},"Point",[50,51],4.44504,51.15662,{"lat":51,"lon":50},[54,56],{"name":55,"role":31,"phone":32,"phoneExt":18,"email":33},"Karolien Dams, MD",{"name":57,"role":31,"phone":36,"phoneExt":18,"email":37},"Rita Jacobs, MD",{"type":28,"investigatorFullName":27,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Principal Investigator, MD, senior staff intensive care",[61],{"name":62,"class":63},"CytoSorbents Europe GmbH","INDUSTRY","100522161","cooley--study-acute-on-chronic-liver-failure-using-the-cytosorb-device-100522161",false,"NCT06079021","COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device","COOLEY","Inclusion Criteria:\n\n* adult patients (≥ 18 years) admitted to the University Hospital of Antwerp (UZA), Belgium.\n\n  * Written informed consent from patient or if not possible due to encephalopathy (\\> grade 2): legal representative\n  * acute-on-chronic liver failure (ACLF) grade ≥ 2:\n\n    * Acute decompensation event (identifiable trigger)\n    * Hepatic encephalopathy grade ≥ 2\n    * Acute kidney injury (AKI) according to Kidney Disease: Improving Global Outcome (KDIGO) criteria stage 3 (≥ 3-fold increase of serum creatinine OR increase of serum creatinine to ≥ 4 mg\u002Fdl OR urine output ≤ 0.3 ml\u002Fkg\u002Fh for ≥ 24 hours OR anuria for ≥ 12 hours)\n    * Serum bilirubin ≥ 10 mg\u002Fdl\n    * Hemodynamic instability with vasopressor support (norepinephrine \\> 0.05 mcg\u002Fkg\u002Fmin)\n\nExclusion Criteria:\n\n* • known patient will against participation in the study or against the measures applied in the study\n\n  * a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours\n  * no complete remission of malignancy including hepatocellular carcinoma within the past 12 months\n  * ongoing intermittent or CRRT before study inclusion","ALL","18 Years",{"count":74,"type":75},20,"ESTIMATED","INTERVENTIONAL",[78],"NA","A Prospective, Single-Center trial, in Patients With Acute on Chronic Liver Failure. Study of Standard Medical Care Plus CytoSorb® Compared to Standard Medical Care Alone in a historical group.",[81,82,83,84],"Acute-On-Chronic Liver Failure","Anticoagulant Adverse Reaction","Sarcopenia","Ultrasonography",[86,87,88,89,90,91,92,93],"acute on chronic liver failure","sarcopenia","citrate anticoagulation","low molecular weight heparins","hand grip strength","skeletal muscle ultrasound","hemoadsorption","CRRT","2026-04-27",{"date":96,"type":97},"2026-05-01","ACTUAL",{"date":99,"type":97},"2024-06-08",{"date":101,"type":75},"2027-12-31",{"name":5,"class":6},1]